1984
DOI: 10.1111/j.1365-2125.1984.tb02489.x
|View full text |Cite
|
Sign up to set email alerts
|

Oxprenolol placental transfer, plasma concentrations in newborns and passage into breast milk.

Abstract: Thirty-two pregnant hypertensive patients were treated with oxprenolol administered in combination with dihydralazine as Trasipressolg tablets. Before delivery, oxprenolol was demonstrable in the maternal plasma and the amniotic fluid. The free fraction of oxprenolol in the maternal serum (15% + 7.8; mean + s.d.; n = 25) was similar to that in normal serum. At the end of delivery, oxprenolol was found in both the maternal and umbilical plasma in most cases. Measurable, but low oxprenolol concentrations were pr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
8
0

Year Published

1985
1985
2015
2015

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 22 publications
(8 citation statements)
references
References 9 publications
0
8
0
Order By: Relevance
“…This is the case with betaxolol, in which the urinary elimination is not the main elimination way , Under these conditions, short half-life (in the adult) is not necessarily a strong argument for choosing a beta-blocking drug during pregnancy, all the more so when the betablocker is metabolized actively with plasma concentrations higher than those of the parent drug, and eliminated more slowly than it (table II). et al [1984] Even with the absence of precise pharmacokinetic data, we know that these type of drugs are often found well after birth, sometimes 2 or 3 days later, in concentrations considered as beta-blocking [Sandström et al, 1982;Boutroy et al, 1982;Sioufi et al, 1984], exposing the child, there fore, to longer drug risks than we had supposed.…”
Section: Placental Transfer Of Beta-blocking Drugsmentioning
confidence: 99%
“…This is the case with betaxolol, in which the urinary elimination is not the main elimination way , Under these conditions, short half-life (in the adult) is not necessarily a strong argument for choosing a beta-blocking drug during pregnancy, all the more so when the betablocker is metabolized actively with plasma concentrations higher than those of the parent drug, and eliminated more slowly than it (table II). et al [1984] Even with the absence of precise pharmacokinetic data, we know that these type of drugs are often found well after birth, sometimes 2 or 3 days later, in concentrations considered as beta-blocking [Sandström et al, 1982;Boutroy et al, 1982;Sioufi et al, 1984], exposing the child, there fore, to longer drug risks than we had supposed.…”
Section: Placental Transfer Of Beta-blocking Drugsmentioning
confidence: 99%
“…Comparison with data for other [3-blockers indicates a higher milk/blood ratios (2.5-10) for acebutolol and a similar value (1.6-4.5) for atenolol, metoprolol, oxprenoloi and propranolol (Boutroy et al 1986;Kulas et al 1984;Liedholm et al 1981;Lundborg et al 1981;SandstrOm and Regardh 1980;Sioufi et al 1984;Thorley et al 1983;White et al 1984).…”
Section: Discussionmentioning
confidence: 53%
“…[10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25] Although the F/M ratio of many compounds was directly cited from literature sources such as clinical studies, the ratio for some compounds (carnitine, chlordane, chlorpyrifos, dichlorodiphenyldichloroethylene (DDE), diazinon, dicloran, hexachlorobenzene (HCB) heptachlor epoxide, nonachlor, oxychlordane, and phthalimide) was calculated based on the concentration in umbilical cord and maternal blood.…”
Section: Data Setsmentioning
confidence: 99%